Micafungin in premature and non-premature infants: A systematic review of 9 clinical trials

Pediatric Infectious Disease Journal

Volumn 33, Issue 11, 2014, Pages e291-e298

  Manzoni, Paolo ^a   Wu, Chunzhang ^b   Tweddle, Lorraine ^c   Roilides, Emmanuel ^d  

^a S ANNA HOSPITAL   (Italy)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^c ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

^d Aristotle University and Hippokration General Hospital   (Greece)

Author keywords

Antimicrobial; Candidiasis; Micafungin; Neonatal; Pediatric

Indexed keywords

MICAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN; LIPOPEPTIDE;

BIRTH WEIGHT; BRAIN HEMORRHAGE; CARDIOPULMONARY INSUFFICIENCY; CHILD; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GESTATIONAL AGE; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOTENSION; INFANT; INVASIVE CANDIDIASIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SYSTEMATIC REVIEW; COMPARATIVE STUDY; INFANT, PREMATURE, DISEASES; LOW BIRTH WEIGHT; MYCOSES; NEWBORN; TERM BIRTH;

ANTIFUNGAL AGENTS; CLINICAL TRIALS AS TOPIC; ECHINOCANDINS; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; LIPOPEPTIDES; MYCOSES; TERM BIRTH;

EID: 84926096705     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000434     Document Type: Review

References (49)

1. Brecht M, Clerihew L, McGuire W. Prevention and treatment of invasive fungal infection in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 2009;94:F65-F69.
2. Roilides E. Invasive candidiasis in neonates and children. Early Hum Dev. 2011;87 Suppl 1:S75-S76.
3. Roilides E, Farmaki E, Evdoridou J, et al. Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates. Eur J Clin Microbiol Infect Dis. 2004;23:745-750.
4. Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al.; National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117:84-92.
5. Zaoutis TE, Heydon K, Localio R, et al. Outcomes attributable to neonatal candidiasis. Clin Infect Dis. 2007;44:1187-1193.
6. Makhoul IR, Sujov P, Smolkin T, et al. Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very low birth weight infants in Israel: a national survey. Pediatrics. 2002;109:34-39.
7. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110(2 pt 1):285-291.
8. López Sastre JB, Coto Cotallo GD, Fernández Colomer B; Grupo de Hospitales Castrillo. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol. 2003;20:153-163.
9. Benjamin DK, DeLong E, Cotten CM, et al. Mortality following blood culture in premature infants: increased with Gram-negative bacteremia and candidemia, but not Gram-positive bacteremia. J Perinatol. 2004;24:175-180.
10. ∗ guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect. 2012;18 (suppl 7):38-52.
11. Juster-Reicher A, Leibovitz E, Linder N, et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection. 2000;28:223-226.
12. Weitkamp JH, Poets C F, Sievers R, et al. Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection. 1998;26:11-15.
13. Manzoni P, Galletto P, Rizzollo S, et al. Liposomal amphotericin B does not induce nephrotoxicity or renal function impairment in premature neonates. Early Hum Dev. 2012;88 (suppl 2):S86-S91.
14. Castagnola E, Jacqz-Aigrain E, Kaguelidou F, et al. Fluconazole use and safety in the nursery. Early Hum Dev. 2012;88 (suppl 2):S11-S15.
15. Frattarelli DA, Reed MD, Giacoia G P, et al. Antifungals in systemic neonatal candidiasis. Drugs. 2004;64:949-968.
16. Manzoni P, Benjamin DK Jr, Franco C, et al. Echinocandins for the nursery: an update. Curr Drug Metab. 2013;14:203-207.
17. Zaoutis TE, Foraker E, McGowan KL, et al. Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals. Diagn Microbiol Infect Dis. 2005;52:295-298.
18. Pfaller MA, Messer SA, Hollis RJ, et al. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J Clin Microbiol. 2009;47:3185-3190.
19. Queiroz-Telles F, Berezin E, Leverger G, et al.; Micafungin Invasive Candidiasis Study Group. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008;27:820-826.
20. Heresi G P, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J. 2006;25:1110-1115.
21. Hope W W, Smith PB, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother. 2010;54:2633-2637.
22. Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J. 2009;28:412-415.
23. ClinicalTrials.gov. NCT00606268. A study of safety and pharmacokinetics of repeated dose of micafungin as antifungal prophylaxis in children and adolescents who undergo hematopoietic stem cell tansplantation. 2014. Available at: http://clinicaltrialgov/ct2/show/NCT00606268?term=NCT00606268&rank=1. Accessed September 9, 2013.
24. ClinicalTrials.gov. NCT00607763. Study of mycamine in infants and toddlers with fungal nfections to evaluate safety and blood levels of the drug. 2014. Available at: http://clinicaltrialgov/ct2/show/NCT00607763?term=NCT00607763&rank=1. Accessed September 9, 2013.
25. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006;53:337-349.
26. Benjamin DK Jr, Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther. 2010;87:93-99.
27. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, openlabel, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis. 2005;24:654-661.
28. van Burik JA, Ratanatharathorn V, Stepan DE, et al.; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407-1416.
29. Tabata K, Katashima M, Kawamura A, et al. Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections. Biol Pharm Bull. 2006;29:1706-1711.
30. Wiederhold N P, Cota JM, Frei CR. Micafungin in the treatment of invasive candidiasis and invasive aspergillosis. Infect Drug Resist. 2008;1:63-77.
31. Kawada M, Fukuoka N, Kondo M, et al. Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants. Pediatr Infect Dis J. 2009;28:840-842.
32. Arrieta AC, Maddison P, Groll AH. Safety of micafungin in pediatric clinical trials. Pediatr Infect Dis J. 2011;30:e97-e102.
33. Jarvis B, Figgitt D P, Scott LJ. Micafungin. Drugs. 2004;64:969-982; discussion 983.
34. Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis. 2004;36:372-379.
35. Horwitz E, Shavit O, Shouval R, et al. Evaluating real-life clinical and economical burden of amphotericin-B deoxycholate adverse reactions. Int J Clin Pharm. 2012;34:611-617.
36. Turkova A, Roilides E, Sharland M. Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy - is there a 'right' choice? Curr Opin Infect Dis. 2011;24:163-171.
37. Baley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in very low-birth-weight infants: therapeutic toxicity. Pediatrics. 1984;73:153-157.
38. Wang JL, Chang CH, Young-Xu Y, et al. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother. 2010;54:2409-2419.
39. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005;49:3317-3324.
40. Ascher S, Smith PB, Benjamin DK Jr. Safety of micafungin in infants: insights into optimal dosing. Expert Opin Drug Saf. 2011;10:281-286.
41. Caudle KE, Inger AG, Butler DR, et al. Echinocandin use in the neonatal intensive care unit. Ann Pharmacother. 2012;46:108-116.
42. Watt K, Benjamin DK Jr, Cohen-Wolkowiez M. Pharmacokinetics of anti-fungal agents in children. Early Hum Dev. 2011;87 (Suppl 1):S61-S65.
43. Steinbach WJ, Roilides E, Berman D, et al.; International Pediatric Fungal Network. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J. 2012;31:1252-1257.
44. Kawaguchi C, Arai I, Yasuhara H, et al. Efficacy of micafungin in treating four premature infants with candidiasis. Pediatr Int. 2009;51:220-224.
45. Oeser C, Vergnano S, Naidoo R, et al. Neonatal invasive fungal infection in England 2004-2010. Clin Microbiol Infect. [published online ahead of print January 30, 2014]. doi: 10.1111/1469-0691.12578.
46. Vogiatzi L, Ilia S, Sideri G, et al. Invasive candidiasis in pediatric intensive care in Greece: a nationwide study. Intensive Care Med. 2013;39: 2188-2195.
47. Chitnis AS, Magill SS, Edwards JR, et al. Trends in Candida central line-associated bloodstream infections among NICUs, 1999-2009. Pediatrics. 2012;130:e46-e52.
48. Pammi M, Holland L, Butler G, et al. Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis. Pediatr Infect Dis J. 2013;32:e206-e216.
49. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45:883-893.